A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

By Wafaa B. Alsoussi, J. Turner, J. Case, Haiyan Zhao, A. Schmitz, Julian Q. Zhou, Rita E. Chen, T. Lei, Amena A. Rizk, Katherine M McIntire and 12 more. 2020

200 citations recorded by the source corpus.

Key Points Generation and screening of anti–SARS-CoV-2 RBD mAbs reveal a potently protective Ab. mAb 2B04 potently neutralizes SARS-CoV-2 in vitro. mAb 2B04 protects mice from morbidity in a murine model of SARS-CoV-2 infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.

Subfields: Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. D. Veesler
2. A. Walls
3. Ralph S. Baric
4. Jesse D. Bloom

Citations in the corpus

• Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, positive): “provide in vivo protection against SARS-CoV-2 challenge in small animals and non-human primates (Alsoussi et al., 2020; Wu et al., 2020; Zost et al., 2020).”
• Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition (2020, unknown): “Both passively-administered and vaccine-induced anti-RBD neutralizing antibodies protect against SARS-CoV-2 in animals (Alsoussi et al., 2020; Cao et al., 2020; Hassan et al., 2020; Rogers et al., 2020; Walls et al., 2020a; Wu et al., 2020; Zost et al., 2020a) , and preliminary evidence suggests…”
• A human coronavirus evolves antigenically to escape antibody immunity (2020, result): “These findings in humans are corroborated by a multitude of animal studies showing that neutralizing antibodies to the SARS-CoV-2 spike protect against infection and disease (Alsoussi et al., 2020; McMahan et al., 2020; Walls et al., 2020; Zost et al., 2020).”
• Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein (2021, unknown): “Previous studies have demonstrated that the RBD region is a key target for potently neutralizing antibodies (Alsoussi et al., 2020; Barnes et al., 2020; Baum et al., 2020a; Hansen et al., 2020; Hassan et al., 2020; Zost et al., 2020a).”